
Artivion (AORT) Stock Forecast & Price Target
Artivion (AORT) Analyst Ratings
Bulls say
Artivion Inc has demonstrated a significant improvement in its operating margin, which reached 17.8%, reflecting a year-over-year increase of 770 basis points and exceeding initial estimates. The company's adjusted EBITDA margin also rose to 18.1%, with a 170 basis point improvement, showcasing robust operational efficiency. Furthermore, management anticipates continued growth in gross margins and EBITDA margins, alongside revenue contributions from new product launches, indicating a strong outlook supported by strategic international expansion and a solid product pipeline.
Bears say
Artivion Inc. faces several significant risks that contribute to a negative outlook, including potential delays in clinical trials, disappointing sales from new products, and the adverse financial impact of GLP-1 weight loss drugs. Recent financial performance has been undermined by a cybersecurity incident, which resulted in a revenue miss of approximately $4.5 million, highlighting vulnerabilities in the company's operational stability and growth trajectory. Additionally, revenue growth has decelerated sharply, from 9.5% in the third quarter to just 3.5% in the fourth quarter of 2024, raising concerns about the sustainability of performance and the effectiveness of new product introductions and international expansion strategies.
This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.
Artivion (AORT) Analyst Forecast & Price Prediction
Start investing in Artivion (AORT)
Order type
Buy in
Order amount
Est. shares
0 shares